본문 바로가기

Predictive Value of F-18-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer

Predictive Value of 18F-FDG PET/CT for Assessment of Tumor Response to Neoadjuvant Chemotherapy in Bladder Cancer

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q1Scopus Q3
저널
CLINICAL NUCLEAR MEDICINE48(7) · pp.574 · 2023
피인용
Web of Science 9Scopus 10
FWCI (Scopus)
1.05
JCR IF
JCR 2022 10.6
ISSN
0363-9762

저자

  1. 고우석제1저자Pusan Natl Univ Hosp, Dept Internal Med, Busan, South Korea
  2. 김성장교신저자Pusan Natl Univ, Dept Nucl Med, Sch Med, Yangsan, South Korea

초록

ObjectiveThe purpose of the current study was to evaluate the diagnostic accuracies of F-18-FDG PET/CT for prediction of tumor response to neoadjuvant chemotherapy in bladder cancer (BC) patients through a systematic review and meta-analysis.Patients and MethodsThe PubMed, Cochrane database, and Embase database were searched from inception through November 30, 2022 for studies evaluating diagnostic performance of F-18-FDG PET/CT for prediction of tumor response to neoadjuvant chemotherapy in BC patients. Based on data extracted from patient-based and lesion-based analysis, we calculated the pooled sensitivity and specificity with the 95% confidence intervals (CIs). Also, we calculated positive and negative likelihood ratios (LR+ and LR-), and constructed summary receiver operating characteristic curves.ResultsAcross 5 studies (12 results), the pooled sensitivity of F-18-FDG PET/CT was 0.84 (95% CI, 0.72-0.91), and the pooled specificity was 0.75 (95% CI, 0.59-0.86). Likelihood ratio (LR) syntheses gave an overall positive likelihood ratio (LR+) of 3.3 (95% CI, 2.0-5.6) and negative likelihood ratio (LR-) of 0.22 (95% CI, 0.12-0.38). The pooled diagnostic odds ratio was 15 (95% CI, 7-36). The pooled sensitivity of F-18-FDG PET/CT for prediction of pathologic complete response was 0.68 (95% CI, 0.56-0.78), and the pooled specificity was 0.77 (95% CI, 0.60-0.88). The pooled sensitivity of F-18-FDG PET/CT for prediction of clinical response and nonresponse was 0.94 (95% CI, 0.85-0.98), and a pooled specificity was 0.73 (95% CI, 0.42-0.91).Conclusions(18)F-FDG PET/CT showed a good diagnostic performance for prediction of tumor response to neoadjuvant chemotherapy in BC patients.

키워드

F-18-FDGPETCTpathologic responsebladder cancerneoadjuvant chemotherapyDIAGNOSTIC-TEST ACCURACYPATHOLOGICAL RESPONSERADICAL CYSTECTOMYMETAANALYSISSURVIVALQUALITYBIAS

식별자

Scopus EID
2-s2.0-85161875076
WoS UID
001000837700016